What Is PT-141? Research Evidence & Profile

What Is Bremelanotide (PT-141)?

Bremelanotide (PT-141) is a peptide entry identified by the Bremelanotide and PT-141 names. This page identifies the material as Bremelanotide (PT-141), with amino acid count 7; synonyms PT-141. The Bremelanotide (PT-141) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

10ClinicalTrials.gov query records

121PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Bremelanotide (PT-141) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Bremelanotide (PT-141), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT023389602. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder	Phase 3	Completed	Hypoactive Sexual Desire Disorder	2021-01-28
NCT04943068A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)	Phase 3	Completed	Hypoactive Sexual Desire Disorder	2024-11-13
NCT03973047Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran	Phase 1	Completed	Nausea	2022-04-04
NCT01382719Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder	Phase 2	Completed	Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder	2014-12-18
NCT05709444A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease	Phase 2	Completed	Kidney Disease	2024-10-17
NCT023330711. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder	Phase 3	Completed	Hypoactive Sexual Desire Disorder	2021-04-09

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

PT-141 Palatin.

Current opinion in investigational drugs (London, England : 2000) · 2004 Apr

PMID 15134289

Selected PubMed record

Bremelanotide.

Journal not stated · 2012

PMID 34436837

Selected PubMed record

Bremelanotide.

Journal not stated · 2006

PMID 31369224

Selected PubMed record

Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.

Journal of midwifery & women's health · 2021 Nov

PMID 34510696

Selected PubMed record

Bremelanotide: First Approval.

Drugs · 2019 Sep

PMID 31429064

Selected PubMed record

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

The journal of sexual medicine · 2006 Jul

PMID 16839319

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Bremelanotide (PT-141)
Available Specifications: 10mg
Pack Format: 10 Vials
CAS Number: 189691-06-3
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.2 g/mol
Amino Acid Count: 7
Sequence: Cyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH with a side-chain lactam bridge between Asp and Lys; N-terminal acetylation and incorporation of norleucine and D-Phe confer protease resistance (full sequence per COA).
Synonyms: PT-141
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 9941379 · Product form must still be matched to the catalogue and batch record.

Research Tools for Bremelanotide (PT-141)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

An FDA-approved bremelanotide drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Bremelanotide (PT-141) Research Summary

Identity

Bremelanotide (PT-141); specifications: 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

10 registry records and 121 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

An FDA-approved bremelanotide drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug.

Bremelanotide (PT-141) is represented here by the catalogue identity Bremelanotide (PT-141). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Bremelanotide (PT-141) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Bremelanotide (PT-141), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 10 ClinicalTrials.gov records and 121 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, An FDA-approved bremelanotide drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Bremelanotide (PT-141) FAQ

What is Bremelanotide (PT-141)?

What research records are indexed for Bremelanotide (PT-141)?

The synchronized query returned 10 ClinicalTrials.gov records and 121 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Bremelanotide (PT-141) FDA approved?

An FDA-approved bremelanotide drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.